NO20015112L - Anvendelse av glykosylceramidsynteseinhibitorer ved terapi - Google Patents
Anvendelse av glykosylceramidsynteseinhibitorer ved terapiInfo
- Publication number
- NO20015112L NO20015112L NO20015112A NO20015112A NO20015112L NO 20015112 L NO20015112 L NO 20015112L NO 20015112 A NO20015112 A NO 20015112A NO 20015112 A NO20015112 A NO 20015112A NO 20015112 L NO20015112 L NO 20015112L
- Authority
- NO
- Norway
- Prior art keywords
- therapy
- synthesis inhibitors
- glycosylceramide
- glycosylceramide synthesis
- inhibitors
- Prior art date
Links
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909064.9A GB9909064D0 (en) | 1999-04-20 | 1999-04-20 | Therapies |
| PCT/GB2000/001563 WO2000062780A1 (en) | 1999-04-20 | 2000-04-20 | Use of glucosylceramide synthesis inhibitors in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20015112D0 NO20015112D0 (no) | 2001-10-19 |
| NO20015112L true NO20015112L (no) | 2001-12-10 |
Family
ID=10851915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015112A NO20015112L (no) | 1999-04-20 | 2001-10-19 | Anvendelse av glykosylceramidsynteseinhibitorer ved terapi |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6683076B2 (no) |
| EP (1) | EP1171129A1 (no) |
| JP (1) | JP2002542195A (no) |
| AU (1) | AU776947B2 (no) |
| BR (1) | BR0009868A (no) |
| CA (1) | CA2368814C (no) |
| GB (1) | GB9909064D0 (no) |
| IL (2) | IL145907A0 (no) |
| MX (1) | MXPA01010706A (no) |
| NO (1) | NO20015112L (no) |
| WO (1) | WO2000062780A1 (no) |
| ZA (1) | ZA200108413B (no) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| GB9909066D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| WO2000066105A2 (en) * | 1999-04-30 | 2000-11-09 | The Trustees Of Boston College | Treatment of epilepsy with imino sugars |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU2003246942B2 (en) * | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| AU2003248960B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| US20060104901A1 (en) * | 2002-08-27 | 2006-05-18 | Angus Moodycliffe | Preventing or treating epithelial tissue damage or hair loss |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
| US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
| WO2005123055A2 (en) * | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| US7884115B2 (en) * | 2004-09-28 | 2011-02-08 | Allergan, Inc. | Methods and compositions for the treatment of pain and other neurological conditions |
| GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| US8961962B2 (en) | 2007-01-05 | 2015-02-24 | Mount Sinai School Of Medicine | Acid ceramidase and mammalian cell survival |
| US20100190792A1 (en) * | 2007-03-06 | 2010-07-29 | Allergan, Inc | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US8173683B2 (en) | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| PT2481407T (pt) * | 2007-03-06 | 2018-12-28 | Allergan Inc | Compostos para utilização no tratamento de distúrbios cognitivos |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| CA3040973A1 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
| PL2854910T3 (pl) | 2012-06-01 | 2020-07-27 | Icahn School Of Medicine At Mount Sinai | Poziomy ceramidu w leczeniu i zapobieganiu infekcjom |
| CA2905449C (en) | 2013-03-14 | 2024-09-10 | Icahn School Of Medicine At Mount Sinai | THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| AU2021217816A1 (en) | 2020-02-03 | 2022-08-11 | Gt Gain Therapeutics Sa | Combination therapy for treating MPS1 |
| IT202000008917A1 (it) | 2020-04-24 | 2021-10-24 | Biovalley Invest Partner S R L | Composizioni antivirali |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798366A (en) * | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
| US6177447B1 (en) * | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| AU8286998A (en) * | 1997-07-03 | 1999-01-25 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Genes for niemann-pick type c disease |
| US6610703B1 (en) * | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| ATE234626T1 (de) * | 1999-07-26 | 2003-04-15 | Searle & Co | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten |
-
1999
- 1999-04-20 GB GBGB9909064.9A patent/GB9909064D0/en not_active Ceased
-
2000
- 2000-04-20 CA CA2368814A patent/CA2368814C/en not_active Expired - Lifetime
- 2000-04-20 AU AU41333/00A patent/AU776947B2/en not_active Expired
- 2000-04-20 EP EP00920922A patent/EP1171129A1/en not_active Ceased
- 2000-04-20 WO PCT/GB2000/001563 patent/WO2000062780A1/en not_active Ceased
- 2000-04-20 JP JP2000611916A patent/JP2002542195A/ja active Pending
- 2000-04-20 MX MXPA01010706A patent/MXPA01010706A/es active IP Right Grant
- 2000-04-20 BR BR0009868-0A patent/BR0009868A/pt not_active Application Discontinuation
- 2000-04-20 IL IL14590700A patent/IL145907A0/xx unknown
-
2001
- 2001-10-12 IL IL145907A patent/IL145907A/en not_active IP Right Cessation
- 2001-10-12 ZA ZA200108413A patent/ZA200108413B/xx unknown
- 2001-10-19 US US10/007,306 patent/US6683076B2/en not_active Expired - Lifetime
- 2001-10-19 NO NO20015112A patent/NO20015112L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL145907A0 (en) | 2002-07-25 |
| US6683076B2 (en) | 2004-01-27 |
| BR0009868A (pt) | 2002-01-08 |
| GB9909064D0 (en) | 1999-06-16 |
| AU776947B2 (en) | 2004-09-30 |
| CA2368814C (en) | 2010-09-07 |
| IL145907A (en) | 2011-05-31 |
| MXPA01010706A (es) | 2002-08-20 |
| NO20015112D0 (no) | 2001-10-19 |
| JP2002542195A (ja) | 2002-12-10 |
| WO2000062780A1 (en) | 2000-10-26 |
| EP1171129A1 (en) | 2002-01-16 |
| CA2368814A1 (en) | 2000-10-26 |
| AU4133300A (en) | 2000-11-02 |
| ZA200108413B (en) | 2003-03-26 |
| US20020115667A1 (en) | 2002-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20015112D0 (no) | Anvendelse av glykosylceramidsynteseinhibitorer ved terapi | |
| NO20014858D0 (no) | Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi | |
| EE200100370A (et) | Teraapias kasutatavad spirofuropüridiinide uued aralküülamiinid | |
| ZA200306488B (en) | Benzamides and related inhibitors of factor Xa. | |
| HUP0203289A3 (en) | Benzamides and related inhibitors of factor xa | |
| DK1268481T3 (da) | Inaseinkibitorer som terapeutiske midler | |
| DE60020100D1 (de) | Dimerverbindungen und als inhibitoren der neuramidinase | |
| GB0013378D0 (en) | Use of therapeutic benzamide derivatives | |
| AU2001294515A1 (en) | Use of stat-6 inhibitors as therapeutic agents | |
| GB0025782D0 (en) | Use of inhibitors | |
| NO20015274D0 (no) | ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav | |
| NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| NO20020365D0 (no) | Oligonukleotider for inhibering av ekspresjonen av humant EG5 | |
| ID30226A (id) | Komposisi penat rambut | |
| AU6749201A (en) | Use of stilbene derivatives for dandruff treatment | |
| EE200100611A (et) | NOS inhibiitorite uued farmatseutilised kombinatsioonid | |
| EE200100623A (et) | Melatoniini terapeutiline kasutamine | |
| NO20024777L (no) | Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte | |
| NO20024776D0 (no) | Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte | |
| EE200100084A (xx) | NOS inhibiitorite uued farmatseutilised kasutusv�imalused | |
| NO20010569D0 (no) | Proteaseinhibitorer for anvendelse ved behandling av psoriasis | |
| ID30381A (id) | Penggunaan arilalkanoilpiridazina | |
| ID27014A (id) | Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi | |
| AU2001240885A1 (en) | Use of glucosylceramide synthesis inhibitors in brain cancer therapy | |
| NO20023243D0 (no) | Ny terapeutisk anvendelse av enoxaparin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |